SHANGHAI, April 24, 2026 /PRNewswire/ — Dingdong (Cayman) Limited (“Dingdong” or the “Company”) (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced supply chain capabilities, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 24, 2026.
The Annual Report can be accessed on the Company’s investor relations website at https://ir.100.me. The Company will also provide a hard copy of its Annual Report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request.
About Dingdong (Cayman) Limited
Dingdong is the leading fresh grocery e-commerce company in mainland China, with sustainable long-term growth. The Company directly provides users and households with fresh groceries, prepared food, and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. Leveraging its deep insights into consumers’ evolving needs and its strong food innovation capabilities, Dingdong has successfully launched a series of private label products spanning a variety of food categories. Many of Dingdong’s private label products are produced at its own production plants, allowing it to more efficiently produce and offer safe and high-quality food products. Dingdong aims to be the first choice for fresh and food shopping.
For more information, please visit: https://ir.100.me.


Đề xuất
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Media Advisory-Ontario Health Coalition/Large cross-province protests this Saturday: Ford gov’t pushing our hospitals into deficit & cuts while paying more to privatize their services
Changan Group Unveils Updated “Vast Ocean Plan 2.0” and highlight Next-Generation BlueCore Hybrid at Auto China 2026
Kerry Properties Presents Asia’s Signature Ice Hockey Event
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
Yunji Files 2025 Annual Report on Form 20-F